Cellvax Expands its Preclinical Service Offers by Moving to a New Laboratory Facility With an Access to Large Animals and a Number of New Technical Plat-Forms

Paris, March 31, 2010 (ots/PRNewswire) - Cellvax is a French service
company which provides complete in vitro & in vivo preclinical
innovating services allowing to accelerate the drug development
process for unmet needs related with severe human diseases, mainly in
oncology field.

Cellvax was created in 2001 as a French SME by a motivated and
complementary team consisting of scientists and experts in these
fields. By offering its know-how and its capacity of innovation,
Cellvax has successfully accomplished numerous in vitro and in vivo
studies for different companies in Europe, Israel and in the world.

Cellvax's expertise is based on its know-how in in vitro models,
especially original in vivo models. These services can be offered to
all laboratories involving in anti-cancer drug development process.
These proposed services adapt to the validation and development of
anti-cancer drug candidates and are fully validated such as
sub-cutaneous and orthotopic tumors models in animals; in vitro and
in vivo angiogenesis models; an original "Nodule" system, tumor
invasion tests, in vivo imaging, bio-distribution, pharmacokinetics,
toxicity, histological analysis, biomarker studies, ...

Cellvax is always ready to obey market evolution and to satisfy
its customers' specific needs all over the world. In order to enhance
its development and continuously satisfy its customers, Cellvax has
recently moved to a new laboratory facility, just on the border of
Paris, inside "Ecole Nationale Vétérinaire Alfort" (ENVA). The ENVA
is one of the oldest and largest veterinary universities in Europe,
created in 1766, with an easy access by subway. The ENVA is located
on a large surface of 110 000 metres squared, with more than one
thousand people (Scientists, Professors, technicians, students, ...)
working here. In this new facility, Cellvax is able to provide to its
customers a number of new services especially with different species
of animals (mice, rats, rabbits, dogs, minipigs, etc.), spontaneous
naturally-developed tumors, in vivo imaging plat-forms, MRI, Scanner,
Scintigraphy, histological analysis, biomarkers.

In summary, Cellvax is able to provide to its customers the
services not only in small animals, but also in large animals in a
more efficient way.

Contact Cellvax: Ming Wei, Ph.D.
President & CEO
Ecole Nationale Vétérinaire Alfort
Telephone: +33-(0)1-43-76-32-65; Mobile: +33-(0)6-71-43-47-51.
E-mail: ming@cellvax-pharma.com

Web Site: http://www.cellvax-pharma.com/

ots Originaltext: CellVax
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Contact Cellvax: Ming Wei, Ph.D.: President & CEO,
EcoleNationale Vétérinaire Alfort, Telephone: +33-(0)1-43-76-32-65;
Mobile:+33-(0)6-71-43-47-51, E-mail: ming@cellvax-pharma.com